A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant.

MLA

Kuan, Jew Win, et al. “A Pioneer Experience in Malaysia on In-House Radio-Labelling of 131I-Rituximab in the Treatment of Non-Hodgkin’s Lymphoma and a Case Report of High Dose 131I-Rituximab-BEAM Conditioning Autologous Transplant.” Applied Radiation & Isotopes, vol. 116, Oct. 2016, pp. 13–21. EBSCOhost, https://doi.org/10.1016/j.apradiso.2016.07.016.

APA

Kuan, J. W., Law, C. S., Wong, X. Q., Ko, C. T., Awang, Z. H., Chew, L. P., & Chang, K. M. (2016). A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin’s Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant. Applied Radiation & Isotopes, 116, 13–21. https://doi.org/10.1016/j.apradiso.2016.07.016

Chicago

Kuan, Jew Win, Chiong Soon Law, Xiang Qi Wong, Ching Tiong Ko, Zool Hilmi Awang, Lee Ping Chew, and Kian Meng Chang. 2016. “A Pioneer Experience in Malaysia on In-House Radio-Labelling of 131I-Rituximab in the Treatment of Non-Hodgkin’s Lymphoma and a Case Report of High Dose 131I-Rituximab-BEAM Conditioning Autologous Transplant.” Applied Radiation & Isotopes 116 (October): 13–21. doi:10.1016/j.apradiso.2016.07.016.